Catalyst Pharmaceuticals, Inc. (CPRX)

CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...

Catalyst Pharmaceuticals, Inc. (CPRX) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript...

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?...

From a technical perspective, Catalyst Pharmaceutical (CPRX) is looking like an interesting pick, as it just reached a key level of support. CPRX recently overtook the 20-day moving average, and this ...

Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....

Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY)....

The mean of analysts' price targets for Catalyst (CPRX) points to a 47.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

Boston Partners raised its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) by 0.6% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Excha...